Foster Greg A, García Andrés J
Woodruff School of Mechanical Engineering and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA.
Woodruff School of Mechanical Engineering and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA.
Adv Drug Deliv Rev. 2017 May 15;114:266-271. doi: 10.1016/j.addr.2017.05.012. Epub 2017 May 19.
Clinical islet transplantation is an effective therapy in restoring physiological glycemic control in type 1 diabetics. However, allogeneic islets derived from cadaveric sources elicit immune responses that result in acute and chronic islet destruction. To prevent immune destruction of islets, transplant recipients require lifelong delivery of immunosuppressive drugs, which are associated with debilitating side effects. Biomaterial-based strategies to eliminate the need for immunosuppressive drugs are an emerging therapy for improving islet transplantation. In this context, two main approaches have been used: 1) encapsulation of islets to prevent infiltration and contact of immune cells, and 2) local release of immunomodulatory molecules from biomaterial systems that suppress local immunity. Synthetic biomaterials provide excellent control over material properties, molecule presentation, and therapeutic release, and thus, are an emerging platform for immunomodulation to facilitate islet transplantation. This review highlights various synthetic biomaterial-based strategies for preventing immune rejection of islet allografts.
临床胰岛移植是恢复1型糖尿病患者生理血糖控制的有效疗法。然而,来自尸体供体的同种异体胰岛会引发免疫反应,导致急性和慢性胰岛破坏。为防止胰岛受到免疫破坏,移植受者需要终身服用免疫抑制药物,而这些药物会带来令人虚弱的副作用。基于生物材料的策略可消除对免疫抑制药物的需求,是一种改善胰岛移植的新兴疗法。在此背景下,主要采用了两种方法:1)封装胰岛以防止免疫细胞浸润和接触;2)从抑制局部免疫的生物材料系统中局部释放免疫调节分子。合成生物材料能对材料特性、分子呈现和治疗性释放进行出色控制,因此,是促进胰岛移植免疫调节的新兴平台。本综述重点介绍了各种基于合成生物材料的策略,以防止胰岛同种异体移植的免疫排斥。